布美他尼
医学
利尿剂
速尿
心力衰竭
利尿剂
药理学
内科学
心脏病学
生物利用度
药代动力学
临床药理学
水肿
重症监护医学
药品
耐受性
作者
Scott Landman,Hesham Masha,Tzvi Fishkin,Amgad N. Makaryus,William H. Frishman,Wilbert S. Aronow
标识
DOI:10.1097/crd.0000000000001518
摘要
Bumetanide is a valuable loop diuretic utilized in the management of heart failure and chronic kidney disease. Although it accounts for less than 5% of all outpatient loop diuretic prescriptions, its oral bioavailability is highly predictable and generally superior to furosemide, which constitutes over 90% of diuretic prescriptions. Bumetanide is longer-acting and more potent than furosemide; however, many physicians utilize bumetanide as a second-line diuretic when furosemide is ineffective or when intestinal edema limits drug absorption. This review summarizes the pharmacology of bumetanide, its clinical application in patients with heart failure with reduced or preserved ejection fraction, and the factors that contribute to its underutilization despite several pharmacokinetic advantages.
科研通智能强力驱动
Strongly Powered by AbleSci AI